Navigation Links
Jiuzhou Pharmaceutical to acquire API Manufacturing Facility in China

Zhejiang Jiuzhou Pharmaceutical Co., Ltd.“Jiuzhou Pharmaceutical, a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) today announced it has entered into a contractual commitment for the purchase of Suzhou Novartis Pharmaceutical Technology Ltd (SNPT), an API manufacturing facility in Changshu Economic Technology Development Zone, Suzhou, China.

Madam Lirong Hua, Chairman of the Board of Jiuzhou Pharmaceutical, commented, “By acquiring this manufacturing site in Suzhou, Jiuzhou Pharmaceutical can accelerate growth by adding new CDMO projects and develop new products for the market. It comes with an excellent manufacturing facility and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals meeting or exceeding customer expectations and regulatory requirements.”

The SNPT site, is an established and reputable API manufacturing facility and provides a number of lifesaving medicines to patients around the world. As part of the agreement, the parties have committed to sign a long-term supply contract to guarantee continuous supply of products manufactured at SNPT. No impact on jobs is planned and Jiuzhou Pharmaceutical will invest in the site and pursue business development opportunities to optimize the utilization and expand the customer base.

“We look forward to a seamless transition for employees, patients, customers, partners and other stakeholders,” added Madam Hua. “We are impressed by the know-how at the SNPT plant and intend to leverage their expertise to develop new opportunities in the pharmaceutical market, in China and globally.”

The acquisition of the SNPT API manufacturing facility is subject to customary approval process of the competent authorities and will be completed by the end of 2019.

About Jiuzhou Pharmaceutical

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, (Stock code 603456), was formed in 1998.
Jiuzhou Pharmaceutical is committed to the research & development, production, and sale of active pharmaceutical ingredients (APIs). In addition, the company offers one-stop CDMO services in Asia, Europe and North America through its Raybow Pharmaceutical division. Jiuzhou Pharmaceuticals has been honored with a number of industry and government accolades including “Top 100 in the Chinese Pharmaceutical Industry”, “National High-Tech Enterprise,“National Technology Innovation Demonstration Enterprises” and many other notable awards. The Company has a sterling track record with regulatory authorities including the FDA and EDQM and excellent compliance history of EHS. For more information on Jiuzhou, please visit our website.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
3. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
4. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
5. Access Pharmaceuticals Reports First Quarter Results
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
9. Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment
10. Aveo Pharmaceuticals, Inc. Sued by Investor
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
Post Your Comments:
(Date:1/22/2020)... BRUNSWICK, N.J. (PRWEB) , ... January 22, 2020 , ... ... Patent (US 10,500,240) on Terminalia chebula. This newly granted patent expands Natreon’s strong patent ... trials. , The primary claim in this patent is, “a method of treating ...
(Date:1/12/2020)... ... January 12, 2020 , ... FutuRx, ... Innovation - JJDC, and Takeda Ventures, Inc, operating under a tender from the ... Pharma in collaboration with Ramot at Tel-Aviv University and Glasgow University. , ...
(Date:1/10/2020)... ... January 10, 2020 , ... Mymee, a digital care program aimed at solving ... new website features real client success stories, a simplified description of how ... to self-insured employers and payers. , “There were two key drivers in reimagining ...
Breaking Medicine Technology:
(Date:1/10/2020)... ... 10, 2020 , ... The 2020 Maine Boatbuilders Show has a Guinness World ... printed boat by the Advanced Structures and Composites Center at the University of Maine ... amazing boat! The lead developer will also be giving seminars. We are inviting ...
(Date:1/10/2020)... ... ... WellHaven Pet Health, a family of companion animal veterinary hospitals headquartered in Vancouver, ... LEAD WELL with WOMEN. The community will be showcased at the VMX 2020 Women’s ... WOMEN is to empower women, engage all, connect, and help you lead your best ...
(Date:1/10/2020)... Ill. (PRWEB) , ... January 10, 2020 , ... ... Group (SMG3), has announced that it will be attending the HIMSS (Healthcare Information ... 2020. , HIMSS is the can’t-miss health information and technology event of ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... life sciences teams, announced today that the company is rebranding as Red Nucleus ... learning and performance solutions for the life sciences industry. , The addition ...
(Date:1/8/2020)... CHURCH, Va. (PRWEB) , ... January 09, 2020 ... ... of 30 Pharma Companies, An FDAnews/CenterWatch Webinar, Thursday, Jan. 23, 2020 • 1:30-3:00 ... evidence (RWE) and real world data (RWD) to generate evidence and identify gaps ...
Breaking Medicine News(10 mins):